Sickle cell disease (SCD) is a blood disorder caused by a point mutation on the beta globin gene resulting in the synthesis of abnormal hemoglobin. Fetal hemoglobin (HbF) reduces disease severity, but the levels vary from one individual to another. Most research has focused on common variants which differ across populations and hence do not fully account for HbF variation. To investigate rare and common variants influencing HbF levels in SCD, we performed targeted next generation sequencing covering exonic and other significant fetal hemoglobin-associated loci, including BCL11A, MYB, HOXA9, HBB, HBG1, HBG2, CHD4,  KLF1, MBD3, ZBTB7A and PGLYRP1 . Results revealed a range of functionally relevant genetic variants. Notably, there were significantly more deletions in individuals with high HbF levels (11% vs 0.9%). We identified frameshift deletion in individuals with high HbF levels and frameshift insertions in individuals with low HbF. CHD4 and MBD3 genes, interacting in the same sub-network, were identified to have a significant number of pathogenic or non-synonymous mutations in individuals with low HbF levels, suggesting an important role of epigenetic pathways in the regulation of HbF synthesis. This study provides new insights in selecting essential variants associated with extreme HbF levels in SCD.
Introduction
Sickle cell disease (SCD) and thalassemia are the most common hemoglobinopathies worldwide, with 270 million carriers and 300,000 to 500,000 annual births [1] . Up to 70% of global SCD annual births occur in sub-Saharan Africa. Reports show that 50% to 80% of affected children in these countries die annually [2] . Tanzania ranks fifth worldwide regarding the number of children born with SCD, estimated at 8,000-11,000 births annually. 15-20% of the population are SCD carriers (HbAS) and therefore potential parents of future babies with SCD [3, 4] . Without intervention, it is estimated that up to 50% of children with SCD will die before the age of 5 years [1] . Thus, SCD intervention at early stages of life may prevent premature deaths and reduce under-five mortality.
SCD is a monogenic condition resulting from a single mutation in the β-globin gene (HBB), on chromosome 11, leading to the production of an abnormal β-hemoglobin chain (HbS). SCD affects multiple organs and hence is a multisystem disease. Clinical manifestations vary immensely, with some individuals being entirely asymptomatic while others suffer from severe forms of the disease. The marked phenotypic heterogeneity of SCD is due to both, genetic and environmental determinants [5] . A major disease modifier is the presence of fetal hemoglobin (HbF): high HbF levels are associated with reduced morbidity and mortality [6, 7] .
Hemoglobin is a tetrametric molecule composed by 2-alpha-globin and 2 gamma globin molecules in HbF and 2 alpha-globin and two 2 beta-globin molecules in HbA [8] . HbF is normally expressed during the development of the fetus and starts to decline just before birth, when it is replaced by adult hemoglobin (HbA) in normal individuals and hemoglobin S (HbS) in individuals with SCD [9] . Red blood cells of normal adults (HbAA) contain mainly hemoglobin A (HbA), with 2.5-3.5% Hemoglobin A2 (HbA2), and < 1% HbF [10] . However, 10% to 15% of adults possess higher HbF levels (up to 5.0%). Although this has no significant consequences in healthy individuals, HbF background variability in SCD can reach levels with clinical benefit to patients [11] . Consequently, efforts to understand and control the production of HbF in SCD patients may result in interventions of significant clinical benefit to individuals with SCD.
The levels of both HbF and F cells (erythrocytes with measurable amounts of HbF) are highly heritable traits [12] with up to 89% of variation being influenced by genetic factors. The remaining proportion is accounted for by age, sex and environmental factors. It is now clear that HbF is a quantitative trait which is shaped by genetic factors both linked and unlinked to the β-globin gene. Three main loci, namely BCL11A on chromosome 2, HMIP on chromosome 6, and HBG on chromosome 11, have been identified across populations as associated with HbF levels [13, 14, 15] . The variants in these loci have been reported to contribute 20-50% of HbF variation in non-African populations, however the impact of these variants is different from one population to another. An example is a strong variant at HMIP, which is rare in the Tanzanian population and hence has a smaller impact on HbF levels there [16, 17] . HbF levels in SCD, as a quantitative trait, is expected to be influenced by other polymorphisms, including insertions/deletions, rare mutations or copy number variations [15] . New genetic and proteomic techniques have led to the identification of several HbF expression regulators have been identified. Kruppel like factor (KLF1) has been reported as one of the key regulators of HbF expression. Reports indicate that KLF1 has dual functions: direct activation of HbF expression through activation of β-globin [18] and an indirect silencing of γ-globin gene through BCL11A1 [19] . Other players within the HbF regulation network that have been reported include GATA1, FOG1 and SOX6, which are erythroid transcription factors and are believed to interact with BCL11A in HbF regulation [20] . In addition, nuclear receptors TR2/TR4 which are associated with corepressors of DNA methyltransferase 1 (DNMT1) and lysine-specific demethylase 1 (LSD1) have also been implicated. DNMT1 and LSD1 are a part of the DRED complex, a known repressor of embryonic and fetal globin genes in adults [21] . Recently, studies of epigenetic pathways of HbF regulation have elucidated the involvement of the nucleosome remodeling and deacetylase (NuRD) complex [22, 23] .
Despite the high prevalence of SCD in Africa, African patient populations remain understudied. Unique insight can be obtained from these patients, considering the substantial African genetic diversity and exceptional mapping resolution. The high burden of SCD in sub Saharan Africa makes it important that genetic studies, ultimately aimed at improved therapeutic intervention, are carried out in African countries. To address this, we conducted a Genome Wide Association Study (GWAS) [16, 17, 24] and candidate genotyping for HbF in Tanzanian individuals with SCD, which led to validation of known HbF variants and identification of novel ones. This report documents a follow-up study aimed at performing in-depth targeted sequencing around previously identified loci to descriptively compare, in detail, discovered polymorphisms between individuals with extreme HbF levels. For the first time, we have conducted targeted next-generation sequencing to investigate known and novel genetic variants and pathways associated with extreme HbF levels in individuals with Sickle cell disease (SCD) in Tanzania. From these selected individuals, we have identified different types of polymorphisms, including SNPs, INDELS, suggesting potential modifier effect. Interestingly, key discovered variants, together with previously identified variants, are enriched in biological pathways that underlie the HbF regulation.
Materials and Methods

Study design and population:
We performed a cross-sectional study involving the Muhimbili SCD cohort, which has been described previously [3] . Written informed consent was obtained for each patient and ethical approval given by the Muhimbili University Research and Publications Committee (MU/RP/AEC/VOLX1/33 and 2017-03-06/AEC/Vol X11/65). The study involved 14 individuals confirmed to have SCD (HbSS or S-β°thalassaemia), over five years old, with extreme HbF levels. Excluded were individuals confirmed to be AS or AA following Hb electrophoresis and HPLC, those with HbF measured at an age of less than 5 years, with inconclusive SCD laboratory diagnosis where a repeat test for confirmation could not be performed, and individuals who were on hydroxyurea therapy.
Phenotyping
Individuals were selected using previously collected HbF data. In this population, the median HbF was 4.6 [Interquartile range (IQR): 2.5-7.7)] [17] and therefore 0-2.5% was considered a low HbF level (HbF≤2.5%) while 7.7% and above was considered a high HbF level (HbF≥7.7%).
Sequencing
DNA was extracted from archived buffy coat samples using the Nucleon BACC II system (GE Healthcare, Little Chalfont, UK). The sequencing panel was adopted from a research panel at King's College London and customized using Illumina DesignStudio (https://designstudio.illumina.com/). Targeted sequencing covered exons and non-coding regions around validated and candidate fetal hemoglobin-influencing loci, including B-cell lymphoma/leukemia 11A (BCL11A), proto-oncogene, transcription factor (MYB), homeobox A9 (HOXA9), hemoglobin subunit beta (HBB), hemoglobin subunit gamma 1 (HBG1), hemoglobin subunit gamma 2 (HBG2), chromodomain helicase DNA binding protein 4 (CHD4), Kruppel like factor 1 (KLF1), methyl-CpG binding domain protein 3 (MBD3), zinc finger and BTB domain containing 7A (ZBTB7A), peptidoglycan recognition protein 1 (PGLYRP1) on chromosomes 2, 6, 7, 11, 12 and 19, respectively (see Table 2 ). Selection of target regions was based on previous associated known and novel loci in the studied population and those reported recently in other populations. Sequencing was performed on the Illumina MiSeq platform at the Kilimanjaro Clinical Research Institute (KCRI), Tanzania, following TruSeq Custom Amplicon Low Input Kit protocol. Figure 1 illustrates and summarizes the pipeline used from alignment to prioritization of mutation. We reconstructed the reads by realigning them to the complete reference genome build hg38 using BWA [25] . The Picard tool kit [26] was used to sort and mark reads duplication, after alignment. We used an ensemble approach implemented in VariantMetaCaller [27] that may find a call consensus in detecting SNPs and short indels [28] . The best practice specific to each caller were adopted [29] . We combined information generated from two independent variant caller pipelines: (1) An incremental joint variant discovery implemented in GATK 3.0 HaplotypeCaller [26] , which calls samples independently to produce gVCF files and leverages the information from the independent gVCF file to produce a final call-set at the genotyping step; (2) bcftools via mpileup [30, 31] variant callers (Figure 1) . The final call-set from each subject group, were produced from VariantMetaCaller [27] . 
Reads Mapping, Alignment, Variant Calling and Variant Calling Quality Control
Annotation, In Silico Prediction of Mutation and Prioritization
High confidence variants were called using VariantMetaCaller [27] from the dataset including 14 Tanzanian SCD patients (nine with high HbF and five with low HbF levels). We used ANNOVAR [32] to perform gene-based annotation to detect whether SNPs cause protein coding changes and to produce a list of the amino acids that are affected. ANNOVAR contains up to 21 different functional scores including SIFT [33, 34] , LRT [35] , MutationTaster, MutationAssessor [36] , FATHMM [37] , fathmm-MKL [38] , RadialSVM, LR, PROVEAN, MetaSVM, MetaLR, DANN, M-CAP, Eigen, GenoCanyon [39] , CADD [40] , GERP++ [41] , Polyphen2 HVAR, Polyphen2 HDIV [42] and PhyloP, SiPhy [43] .
From the resulting functional annotated dataset, we first filtered variants for rarity, exonic variants, non-synonymous, stop codons; predicted functional significance and deleteriousness [33, 34] . First, the resulting functional annotated data set was independently filtered for predicted functional status (of which each predicted functional status is "deleterious" (D), "probably damaging" (D), "disease_causing_automatic" (A) or "disease_causing" (D) [44, 45, 46] from these 21 in silico prediction mutation tools. Recent evaluation of in silico prediction tools for mutation effects suggested these tools are quite similar [47] . However, the evaluation of these tools was conducted mostly in non-African populations. Here we opted for an extreme casting vote approach to retain only a variant if it had at least 17 predicted functional status "D" or "A" out of 21, as one can expect a true in silico mutant variant to similarly be reported from most of these tools. Second, the retained variants were further filtered for rarity, exonic variants, nonsynonymous mutations, yielding a final candidate list of predicted mutant and genetic modifier variants.
Network and Enrichment Analysis
To find out how predicted in silico mutant and modifier genes interact with others at the systems level, we analyzed how the set of all interactive genes from knowledge-based Protein-Protein Interaction (PPI) interacted with our identified in silico mutant genes and the rest of targeted genes, respectively. This to identify potential biological pathways in which these genes participate. To achieve this, we first mapped the identify mutant SNPs to their closest genes. We mapped genes to a comprehensive human Protein-Protein Interaction (PPI) network [48, 49] to identify sub-networks containing mutant and genetics modifier variant genes and their interactions. Using the Enrichr software [50] , we examined how closely these genes within the extracted sub-networks are associated with human phenotypes and elucidate biological processes and pathways in which these genes participate, molecular functions and association with potential human phenotypes. The most significant pathway enriched for genes in the networks were selected from KEGG [51] , Panther [52] , Biocarta [53] and Reactome [54] . Gene ontologies, including molecular functions and biological process, from the Gene Ontology database [55] .
Results
Sample Characterization
This study involved 14 SCD individuals with extreme (9 with high and 5 with low) HbF levels. 
Summary of variants found in individuals with high and low HbF levels
A total of 873 and 1196 highly confident variants were determined in SCD patients with high and low HbF levels, respectively, on chromosomes 2, 6, 7, 11, 12 and 19. Surprisingly, this shows a difference in the overall variation between the two groups of individuals with SCD.
The identified variants are comprised of 77% and 82 % biallelic SNPs, 0.15% and 0.11% multi-allelic SNPs, 11% and 0.9% deletions and 0.9% and 0.7% insertions in patients with high and low HbF levels (adjusted χ2 p-values = 1.16e-03 and 2.96e-06, as compared to uniform distribution), respectively. From these discovered variants, we detect 1 and 0 frameshiftdeletions, 2 and 4 frameshift-insertions, 1 and 1 non-frameshift-insertions, 34 and 41 nonsynonymous, 3 and 3 stop-gain, 49 and 60 synonymous variants in SCD individuals with high/low HbF level, respectively. Based on our targeted chromosomal sequencing, we found significant difference in coverage of variants in the molecular structure (Figure 2 ) between SCD patients with high and low HbF level (adjusted Fisher exact p-value = 6.1e-04), at 3'untranslated region (3'UTR) (2.9% versus 4.2%), 5' untranslated region (5'UTR) (4.2% versus 0.68%), upstream (0.2%, 2.9%). Critically, we observed that patients with high HbF have 0% variants in splicing regions, while patients with low HbF level have 1.48% (Figure 2) . Abbreviations: USig * is the number variant with uncertain significance of pathogenicity.
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Potential pathogenic variants
Although African-specific reported pathogenic variants are underrepresented in current databases of pathogenic variants [56] , here we aimed at descriptively characterizing possible pathogenic variants from the set of polymorphisms in the retained candidate in silico mutant genes and our initial target genes discovery variants between the two patient groups. Following our pipeline and mutation prioritization, we identified six SNPs in genes (ZBTB7A, CHD4, HBB, PGLYRP1, MBD3 and MYB) with functional impact ( Table 2 and Supplementary File: Table S2 ) in both data generated from the SCD patients with high and low HbF levels. Two genes, CHD4 and the MBD3, were found with a difference in the number of pathogenic variants ( Table 3 and Supplementary File: Table S2 ): individuals with SCD with low HbF levels were found to have more pathogenic, benign or uncertain significant pathogenic variants. Individuals with SCD with lower HbF levels had a significantly higher number of variants with insertions at both CHD4 and MBD3 than patients with high HbF levels ( Table 2 and Supplementary File: Table S1 ). While both groups have small numbers of deletion variants, individuals with low HbF level had fewer deletions than those with high HbF level.
Based on Exome Aggregation Consortium (ExAC) database of pathogenic mutation [56] , we found no significant difference in the number of pathogenic variants in both SCD patients with high or low HbF levels in genes (BCL11A), proto-oncogene, transcription factor (MYB), Homeobox A9 (HOXA9), hemoglobin subunit gamma 2 (HBG2), Kruppel like factor 1 (KLF1), zinc finger and BTB domain containing 7A (ZBTB7A) in chromosomes 2, 6, 7, 11, 12 and 19, respectively. Overall, our targeted next generation sequencing of HbF associated genetic loci identified a disproportional number of loci with a few, variants, particularly deletions, present in patients with high levels of HbF. 
Biological pathways and processes associated with genes with high mutational burdens
Independent roles of the identified candidate in silico mutant genes (Supplementary File: Table S1, Figure 2 ) or our initial targeted nine genes are known in Sickle Cell disease. However, how these genes interact with others at the systems level is currently unknown, particularly in African population of Sickle cell patients. As described in method section, using the set of all interactive genes including our identified mutant genes and the rest of targeted genes may contribute in identifying potential Sickle Cell-specific pathways in which modifier and mutant genes participate together in conferring variation in Sickle Cell Disease severity. The identified Protein-Protein Interaction (PPI) sub-network formed from 2 genes (Figure 3A) showed an enrichment of rare variants with deleterious effects was enriched for the PRC2 complex which influence long-term gene silencing through modification of histone tails (P = 0.000004; Figure 3B) , and is highly associated with or involved in the TP-dependent chromatin remodeling (P = 1.6e-12, Figure 3B ) biological process, nominally associated with pallor (P = 0.0014, Figure 3B ). CHD4 and MBD3 were found to be the most important genes (hubs) of sub-network (Figure 4A) , which are nominally associated with the B cell survival pathway (P = 0.018, Figure 4B ), known to be implicated in the ATP-dependent chromatin remodeling biological process (P = 6e-15, Figure 4B ) and associated with polycythemia disorder (P = 0.0001, Figure 4B ). 
Discussion
This is the first study in Africa to conduct targeted next generation sequencing to investigate genetic modifiers and pathways associated with extreme fetal hemoglobin (HbF) in individuals with SCD. Most of the loci (SNPs) that have been found to associate with HbF by GWAS only show possible associations with variants covered by the array chip GWAS. The approach taken in this study was to perform in-depth sequencing around previously identified loci to descriptively compare, in detail, discovered polymorphisms between individuals with extreme HbF levels. We have identified single nucleotide polymorphisms (SNPs), insertions (IN) and deletions (DEL) across 8 targeted regions in chromosomes 2, 6, 7, 11, 12 and 19. We found differing types of polymorphisms, including SNPs and INDELS between individuals with low HbF versus those with high HbF, suggesting potential modifier effect. Interestingly, key discovered variants, together with previously identified variants, are enriched in biological pathways that underlie the HbF regulation.
It is worth also noting that possible structural variants in these patient groups may make the sequencing off between the two groups. Furthermore, current challenges include (1) limitation of variant calling tools in African data [57] , (2) sequencing errors and structural variants in African data [58] and (3) under-representation of African samples in the current reference genome [58, 59] and may contribute to the observed difference in variants discovered in both high and low HbF level in individuals with SCD. We found more deletions in individuals with high HbF than those with low HbF levels indicating their role in HbF synthesis pathways. A number of significant deletions have been reported before, particularly in the globin cluster [60, 61, 62] . In this study, we have identified additional potential deletions across the targeted regions ( Table 2) . We observed more insertions in individuals with high HbF than in those with low HbF. However, frameshift deletions were found more in individuals with high HbF, while frameshift insertions were more prevalent in individuals with low HbF. Frameshift deletions and insertion may lead to abnormal proteins due to shorter or longer sequences, respectively.
We also looked at variants located at untranslated regions (UTR) both at 3' and 5' ends which are involved differently in regulation of gene expression. Interestingly, there were more variants in the 5'UTR in individuals with high HbF levels, whereas there were more variants in the 3'UTR in individuals with low HbF levels. Molecular mechanisms of the 5'UTR include regulating translation of main coding sequences while the 3'UTR contain binding sites for micro RNA (miRNA) which takes part in the timing and rate of translation of the corresponding mRNA. Hence the difference in variants in these two regions between individuals with high HbF versus those with low HbF is notably and may participate in differential in the regulation of HbF synthesis.
We looked specifically at non-synonymous mutations and found that out of the eight targets, six were found to have mutations with functional impact. Of interest, the genes CHD4 and MBD3, functionally interacting in the same sub-network (see Figure 3) , had more pathogenic mutations in individuals with low HbF levels than those with high HbF. CHD4 is a chromatin organization modifier which confers the chromatin remodeling function of the NuRD complex. CHD4 has been reported to repress γ-globin gene expression in mouse [22, 23] . Similarly, MBD3 operates as a NuRD complex and is associated with the transcription factors GATA-1 and FOG-1 to directly regulate genes within the β-globin locus.
The human protein-protein interaction (PPI) (Figure 3A) for CHD4 and MBD3 proteins indicates that they are essential to system survival and hence their biological functions tend to be evolutionary conserved [63] . Thus, in presence of non-synonymous mutations, it is expected that individual components (proteins and interactions) in the system must adapt to a changing environment while maintaining the system's primary function. In this study, we observed that, to maintain its robustness while sustaining its function under fluctuating environmental conditions, the system possibly triggers different mechanisms. This ensures that the network retains the modularity degree in order to provide a selective advantage for the host system by conserving and/or gaining useful functional interactions within the network to ensure an increase of HbF levels. As an illustration, CHD4, as well as MBD3, indirectly interact with KLF1 and MYB, which are potent activators of BCL11A. CHD4 is believed to exert its gamma globin silencing effect by positively regulating the BCL11A and KLF1 genes. In addition, BCL11A and MYB are known to be involved in γ-globin gene regulation, leading to either elevation or reduction of HbF levels [64] . The difference in frequency of non-synonymous mutations in the individuals with high HbF levels versus those with low levels reflect different interactions within this network and the resulting levels of HbF.
Given our study design, we did not perform genetics differentiation test or statistical tests of differences in minor allele frequencies or genotype counts. Instead, we have aimed at descriptively characterizing the proportion of variants between the low/high HbF from high confident variants calling, compare the count of pathogenic variants between the groups and identify potential Sickle Cell-specific pathways in which modifier and mutant genes participate in conferring variation in Sickle Cell severity. Importantly, our current study suggests (1) a difference in the overall variation between Sickle Cell patients with high and low HbF level and, (2) biological pathways include the PRC2 complex which sets long-term gene silencing through modification of histone tails (P = 0.000004; Figure 3B ), hemoglobin's Chaperone (P = 0.001, Figure 4B ) and B-cell Survival (P = 0.018, Figure 4B ). These identified pathways may harbour potential interactive Sickle Cell-specific genes including modifier, mutant and other genes (Figures 3-4 ) in conferring variation in severity among individuals with SCD. This work has focused on the importance of studying both genetic and epigenetic pathways in HbF regulation. Our findings suggest an in-depth whole genome sequencing study to to fully characterize modifier genes implicated in the variation of SCD severity. This approach may contribute to future development of interventions for SCD, including drugs and gene therapy.
